Procurement Report: Letrozole (CAS No: 112809-51-5)

Product Category: Pharmaceutical Active Pharmaceutical Ingredient (API) / Finished Dosage Form (Tablets) Primary Application: Oncology (Hormone Receptor-Positive Breast Cancer)

1. Technical Specifications and Performance Metrics

Letrozole (CAS 112809-51-5) is a non-steroidal aromatase inhibitor. Procurement specifications must distinguish between the raw API and the finished film-coated dosage form, as performance metrics differ significantly.

• Dosage Strength: The industry standard for finished tablets is 2.5 mg per unit.
• Formulation: Available as film-coated tablets. The standard film-coated tablet formulation contains 45 mg of lactose monohydrate per tablet as a filler/binder.
• Administration Protocol: The recommended clinical dose is one 2.5 mg tablet administered once daily, with no restriction regarding food intake (administered without regard to meals).
• Stability & Shelf Life: Typical pharmaceutical stability for Letrozole tablets ranges from 24 to 36 months when stored under standard conditions (controlled room temperature, 20°C to 25°C).
• Solubility & Bioavailability: As an aromatase inhibitor, the drug must maintain high bioavailability to effectively suppress estrogen synthesis.
• Packaging: Typically supplied in blister packs or bottles of 28, 30, or 90 units to align with monthly treatment cycles.

Procurement Recommendation: When sourcing finished products, verify the lactose content (45 mg/tablet) against patient allergies (lactose intolerance). For API sourcing, ensure the Certificate of Analysis (COA) confirms the specific CAS number 112809-51-5 and purity levels exceeding 98.5% (typical B2B range for pharmaceutical grade).

2. Industry Compliance and Quality Assurance

Letrozole is a strictly regulated substance due to its use in treating serious malignancies. Compliance is non-negotiable.

• Regulatory Status: The product has received FDA approval (originally granted July 25, 1997) for the treatment of hormone receptor-positive breast cancer in postmenopausal women.
• Target Demographic Compliance: Procurement contracts must explicitly state that the product is intended only for women of postmenopausal endocrine status. Supplying to premenopausal patients without specific clinical protocols is a compliance risk.
• Quality Control Documentation: Every batch must be accompanied by a Certificate of Analysis (COA) detailing physical and chemical testing results. This includes assay results, impurity profiles, and dissolution testing.
• Manufacturing Standards: Suppliers must adhere to Good Manufacturing Practices (GMP) as defined by the FDA and relevant local health authorities.
• Labeling Requirements: Labels must clearly indicate the indication (postmenopausal breast cancer) and the specific dosage (2.5 mg).

Procurement Recommendation: Require a current COA for every shipment. Do not accept generic "quality certificates" that lack specific batch numbers and test results. Verify that the supplier's facility is listed in the FDA's drug establishment registration database or equivalent regulatory body in the target market.

3. Cost Efficiency and Integration Capabilities

• Pricing Structure: As a generic off-patent drug (originally approved in 1997), Letrozole 2.5 mg tablets are generally cost-effective.
  • Estimated Unit Cost: $0.50 – $2.50 USD per tablet (typical B2B range for generic finished goods, excluding shipping and tariffs).
  • API Cost: Significantly lower per gram, typically ranging from $50 – $150 USD per kg depending on purity and volume (typical B2B range).
• Minimum Order Quantity (MOQ):
  • Finished Goods: MOQs typically range from 1,000 to 5,000 units (1-5 months of supply for a small clinic).
  • API: MOQs typically range from 10 kg to 100 kg.
• Lead Time:
  • Finished Goods: 4 – 8 weeks for standard international shipping.
  • API: 6 – 12 weeks depending on synthesis complexity and raw material availability.
• Integration: The drug is stable and easy to integrate into existing hospital pharmacy inventory systems. It requires no special cold-chain logistics (unlike biologics), reducing warehousing costs.

Procurement Recommendation: Leverage the generic status of the drug to negotiate volume discounts. For hospitals or large pharmacies, prioritize suppliers offering 90-day supply packaging to reduce administrative overhead. Ensure the supplier can handle Just-in-Time (JIT) delivery models to minimize inventory holding costs, given the drug's long shelf life.

4. Typical Use Cases

• Primary Indication: Treatment of hormone receptor-positive (HR+) breast cancer in postmenopausal women.
• Adjuvant Therapy: Used following surgery (lumpectomy or mastectomy) to reduce the risk of cancer recurrence.
• Advanced Disease: Used in the treatment of advanced breast cancer in postmenopausal women who have progressed on prior anti-estrogen therapy.
• Oncology Clinics: Standard stock for outpatient oncology departments managing endocrine therapy.
• Clinical Trials: Sourcing for Phase II and III trials investigating aromatase inhibitors in various breast cancer subtypes.

Procurement Recommendation: Align procurement volumes with the demographic profile of the target patient base. Since the drug is indicated only for postmenopausal women, ensure the supply chain does not inadvertently stock or distribute to facilities treating premenopausal patients without specific oncologist oversight.

5. Long-Term Planning Considerations

• Market Demand Signals: Breast cancer remains one of the most common cancers globally. The shift towards endocrine therapy as a standard of care for HR+ breast cancer ensures stable, long-term demand for Letrozole.
• Supply Chain Resilience: As a generic drug, there are multiple manufacturers globally. However, supply disruptions can occur due to raw material shortages or regulatory changes.
• Patent Status: The drug is off-patent, leading to a highly competitive market with multiple generic manufacturers. This reduces the risk of supply monopolies but increases the need for rigorous quality vetting.
• Regulatory Trends: Increasing scrutiny on excipient safety (e.g., lactose content) and manufacturing site inspections.
• Sustainability: Focus on suppliers utilizing green chemistry principles for API synthesis to meet future ESG (Environmental, Social, and Governance) procurement mandates.

Procurement Recommendation: Develop a multi-sourcing strategy with at least two qualified suppliers to mitigate supply chain risks. Monitor regulatory updates regarding lactose-free formulations, as patient demand for alternative excipients may grow. Plan for inventory levels to cover at least 3-6 months of demand to buffer against global logistics disruptions.

6. Special Product Recommendations

The following table compares different procurement options for Letrozole based on buyer profile and risk factors.

| Product Type | Best-Fit Buyer | Key Specs | Risk Check | Procurement Advice | | :--- | :--- | :--- | :--- :--- | | Generic 2.5mg Film-Coated Tablets | Hospitals, Retail Pharmacies | 2.5 mg dose, 45mg Lactose, FDA approved | Verify lactose content for patient allergies | Prioritize suppliers with FDA/EMA listed facilities; check for 90-day blister packs. | | Letrozole API (Bulk) | Pharmaceutical Manufacturers | CAS 112809-51-5, Purity >98.5% | Verify COA and impurity profiles | Require GMP certification; negotiate volume pricing for >100kg orders. | | Lactose-Free Formulation | Clinics with high lactose-intolerant population | 2.5 mg dose, Alternative excipients | Confirm excipient list on COA | Request samples for dissolution testing; higher cost but reduces adverse event risk. | | Oncology Clinical Trial Supply | Research Institutions | Blister packs, Batch-specific COA, Traceability | Strict chain-of-custody documentation | Ensure supplier can handle randomized, blinded packaging requirements. |

Procurement Recommendation: For general hospital use, the Generic 2.5mg Film-Coated Tablets offer the best balance of cost and availability. For specialized clinics, proactively seek Lactose-Free alternatives to prevent patient non-compliance. Always verify the "Best-Fit" alignment before signing contracts.

7. Frequently Asked Questions (FAQ)

Q1: Is Letrozole suitable for premenopausal women? A: No. Letrozole is indicated only for postmenopausal women. Administering it to premenopausal women is generally contraindicated without specific ovarian suppression protocols, as it may not be effective or safe.

Q2: How should Letrozole tablets be stored? A: Tablets should be stored at controlled room temperature (typically 20°C to 25°C) and protected from moisture. They do not require refrigeration.

Q3: Does the 2.5 mg tablet need to be taken with food? A: No. The recommended dose is administered once daily without regard to meals. It can be taken with or without food.

Q4: What is the standard dosage for breast cancer treatment? A: The standard recommended dose is one 2.5 mg tablet once daily. Treatment duration is typically continuous for 5 years or as directed by the oncologist.

Q5: What is the CAS number for Letrozole? A: The CAS number is 112809-51-5. This is the critical identifier for verifying the chemical substance during procurement.

Q6: Does the standard tablet contain lactose? A: Yes, standard Letrozole 2.5 mg film-coated tablets typically contain 45 mg of lactose monohydrate. Buyers must check the specific excipient list for patients with lactose intolerance.

Q7: How long is the shelf life of Letrozole tablets? A: Typically 24 to 36 months from the date of manufacture, provided they are stored correctly. Always check the expiration date on the specific batch COA.

Q8: Are there specific certifications required for suppliers? A: Yes. Suppliers must provide a Certificate of Analysis (COA) for every batch and operate under GMP (Good Manufacturing Practice) standards. FDA approval or equivalent regulatory clearance is mandatory for finished products.